A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2015

At a glance

  • Drugs Pardoprunox (Primary) ; Levodopa
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms MONDRIAN
  • Sponsors Solvay Pharmaceuticals
  • Most Recent Events

    • 14 Jun 2010 Results have been presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
    • 20 Apr 2010 Additional trial location (Albania) added as reported by ClinicalTrials.gov (NCT00407095) record.
    • 20 Apr 2010 Additional trial location (Albania) added as reported by ClinicalTrials.gov (NCT00407095) record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top